T1	Participants 113 171	operable breast cancer with 0 to 3 positive axillary nodes
T2	Participants 173 187	North American
T3	Participants 545 567	operable breast cancer
T4	Participants 590 737	Women with invasive breast cancer were eligible if there were one to three positive lymph nodes or if the node-negative tumor was greater than 1 cm
T5	Participants 1074 1097	2,882 eligible patients
T6	Participants 967 1053	patients with estrogen receptor (ER) and/or progesterone receptor (PR)-positive tumors
T7	Participants 1500 1522	ER/PR-negative disease
